Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.

Acute myeloid leukemia (AML) isn’t the most commonly known cancer. It is, however, one of the deadliest—an awful rare malignancy of the blood and bone marrow whose victims are already older and frail, ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. Researchers at Baylor College of Medicine, University of Veterinary ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles. Traditional therapies ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...

In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...